(Peter Pitts, President and Co-founder of the Center for Medicine in the Public Interest ) - Consumers purchasing retatrutide online may think they are buying a safe, clinically tested weight-loss drug. They are not. Medical spas and online sellers have built a booming black market around an unapproved investigational drug – exploiting polished websites and professional packaging to sell illegal drugs to unsuspecting Americans. What is especially concerning about today’s version of this deception is how FDA is doing nothing to stop it, allowing this black market to turn into a digital-age Wild West.

Retatrutide is an investigational molecule currently being studied in clinical trials for the treatment of obesity. It has not yet received approval from the Food and Drug Administration (FDA) and cannot be lawfully sold. That is not an opinion. That is the law. And yet sellers are aggressively marketing it as equivalent to – or even superior to – FDA-approved therapies already on the market.

Illicit retatrutide is being sourced from unregistered foreign manufacturers with no assurance of sterility, potency, or ingredient authenticity. When something goes wrong, distributors face no accountability and no obligation to report it. Consumers have no meaningful way of knowing what they are actually injecting – and the consequences are already showing up in hospitals and poison centers across the country.

Documented reports describe hospitalizations for acute kidney damage and severe gastrointestinal distress. One 42-year-old woman was rushed to the emergency room after experiencing severe symptoms from black market “retatrutide” she purchased online. Poison center reports have surged – with hundreds of reports in the first four months of 2026.

FDA’s response to this explosion of illegal drugs – a handful of warning letters with no follow up – amounts to less than a slap on the wrist. Warning letters do not shut down black markets. Arrests and seizures do.

The deeper threat is institutional – every day this market operates without aggressive enforcement, it becomes more entrenched, profitable, and normalized. The message that FDA is sending to these criminal sellers is that there is no cop on the beat. When they turn to even more dangerous and brazen schemes to sell these illegal drugs, it will be that much harder for FDA to put a stop to them when it finally decides to act. That erosion of institutional credibility has consequences that outlast any single drug.

Clinical trials exist because consumer demand is not a substitute for scientific evidence. Allowing investigational peptides to become internet lifestyle products before FDA review and approval is not the democratization of medicine, but the degradation of it.

The FDA must take aggressive steps to shut down this market and must coordinate with the Department of Justice, Customs and Border Protection, and the Federal Trade Commission to pursue seizures, injunctions, and criminal referrals against the sellers and platforms fueling this illegal market. The longer regulators hesitate, the harder this black market becomes to unwind. The FDA must act now – before the window closes to rein in this new frontier for illegal drugs in the digital age.